Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:06:59.877Z.
Consensus retrieved: 2026-10-06T10:22:53.914Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:06:59.877Z.
Quote observation: 2026-10-06T16:04:45.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4980e4284b6230c79d3dcd5f09fe919c7c05eb80d65ab6e095ba480293e97312
Forward PE Ratio (N/A) = Dated Quote Price ($2.42) / Consensus Forward EPS ($-0.75)
FORWARD PE RATIO
N/A
Canton Strategic Holdings Inc
Market Cap
$187.02M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Canton Strategic Holdings Inc (CNTN) | $187.02M | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $188.18M | N/A |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $182.51M | 1.00 |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.58M | N/A |
| RxSight, Inc. (RXST)vs › | $194.15M | N/A |
| Journey Medical Corporation (DERM)vs › | $178.94M | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $176.27M | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $173.82M | N/A |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.76M | N/A |
| Nkarta, Inc. (NKTX)vs › | $172.78M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.42, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.75 | $-0.75 – $-0.75 | 1 | n/m |
| 2027-12-31 | $-0.90 | $-0.90 – $-0.90 | 1 | n/m |
| 2028-12-31 | $-1.05 | $-1.05 – $-1.05 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
